Last updated: 20 June 2022 at 4:14pm EST

Julie Gerberding Net Worth




The estimated Net Worth of Julie L. Gerberding is at least $28.7 Million dollars as of 1 November 2021. Julie Gerberding owns over 96,270 units of Merck & Co Inc stock worth over $15,535,405 and over the last 10 years he sold MRK stock worth over $13,186,320. In addition, he makes $0 as Executive Vice President and Chief Patient Officer, Strategic Communications, and Global Public Policy and Population Health at Merck & Co Inc.

Julie Gerberding MRK stock SEC Form 4 insiders trading

Julie has made over 12 trades of the Merck & Co Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 96,270 units of MRK stock worth $11,043,132 on 1 November 2021.

The largest trade he's ever made was selling 102,073 units of Merck & Co Inc stock on 13 January 2020 worth over $9,119,202. On average, Julie trades about 15,664 units every 72 days since 2015. As of 1 November 2021 he still owns at least 135,432 units of Merck & Co Inc stock.

You can see the complete history of Julie Gerberding stock trades at the bottom of the page.





Julie Gerberding biography

Dr. Julie Louise Gerberding M.D. serves as Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health of the Company., Inc. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Merck’s global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Merck’s ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations. Gerberding joined Merck as president of Merck Vaccines in January 2010. Since then, Merck’s vaccines are reaching more people than ever, and Merck became the global leader in the vaccine market based on sales. In addition, the Sanofi Pasteur MSD joint venture in Europe, Merck’s European vaccine business for which Gerberding is the Board co-chair, has improved in both population reach and financial performance. She also helped lead the successful launch in India of the Merck Wellcome Trust non-profit joint venture for vaccine development, the MSD Wellcome Trust Hilleman Laboratories. Prior to joining Merck, Gerberding served as director of the U.S. Centers for Disease Control and Prevention (CDC) from 2002-2009 and before that served as director of the Division of Healthcare Quality Promotion. Before joining the CDC, Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco (UCSF). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF.



How old is Julie Gerberding?

Julie Gerberding is 64, he's been the Executive Vice President and Chief Patient Officer, Strategic Communications, and Global Public Policy and Population Health of Merck & Co Inc since 2016. There are 9 older and 18 younger executives at Merck & Co Inc. The oldest executive at Merck & Co Inc is Thomas Cech, 73, who is the Independent Director.

What's Julie Gerberding's mailing address?

Julie's mailing address filed with the SEC is 2800 ROCK CREEK PARKWAY, , NORTH KANSAS CITY, MO, 64117.

Insiders trading at Merck & Co Inc

Over the last 15 years, insiders at Merck & Co Inc have traded over $138,980,380 worth of Merck & Co Inc stock and bought 48,209 units worth $1,563,736 . The most active insiders traders include Wendell P Weeks, Kenneth C Frazier, and Douglas M Jr Baker. On average, Merck & Co Inc executives and independent directors trade stock every 15 days with the average trade being worth of $5,050,222. The most recent stock trade was executed by Chirfi Guindo on 5 August 2024, trading 36,901 units of MRK stock currently worth $4,250,995.



What does Merck & Co Inc do?

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.



What does Merck & Co Inc's logo look like?

Merck & Co Inc logo

Complete history of Julie Gerberding stock trades at Cerner and Merck & Co Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
1 Nov 2021 Julie L. Gerberding
EVP and Chief Patient Officer
Option 96,270 $87.84 $8,456,357
1 Nov 2021
135,432
17 Jul 2020 Julie L. Gerberding
EVP and Chief Patient Officer
Sale 36,285 $80.00 $2,902,800
17 Jul 2020
26,577
13 Jan 2020 Julie L. Gerberding
EVP and Chief Patient Officer
Sale 102,073 $89.34 $9,119,202
13 Jan 2020
37,038
7 Nov 2018 Julie L. Gerberding
EVP and Chief Patient Officer
Option 36,218 $54.68 $1,980,400
7 Nov 2018
82,480
15 May 2018 Julie L. Gerberding
EVP and Chief Patient Officer
Sale 9,972 $59.66 $594,930
15 May 2018
45,716
2 May 2017 Julie L. Gerberding
EVP and Chief Patient Officer
Option 3,092 $62.70 $193,868
2 May 2017
46,416
7 Nov 2016 Julie L. Gerberding
EVP and Chief Patient Officer
Option 85,523 $41.53 $3,551,770
7 Nov 2016
124,638
7 Nov 2016 Julie L. Gerberding
EVP and Chief Patient Officer
Option 85,523 $41.53 $3,551,770
7 Nov 2016
124,638
6 May 2016 Julie L. Gerberding
EVP and Chief Patient Officer
Option 4,002 $53.60 $214,507
6 May 2016
40,220
8 May 2015 Julie L. Gerberding
EVP and Chief Patient Officer
Option 46,208 $35.28 $1,630,218
8 May 2015
70,353
1 May 2015 Julie L. Gerberding
EVP and Chief Patient Officer
Option 3,818 $59.86 $228,545
1 May 2015
25,359
22 Aug 2019 Julie L. Gerberding
Director
Sale 7,928 $71.82 $569,389
22 Aug 2019
8,128


Merck & Co Inc executives and stock owners

Merck & Co Inc executives and other stock owners filed with the SEC include: